W
Weiwen Ying
Researcher at Ohio State University
Publications - 57
Citations - 1360
Weiwen Ying is an academic researcher from Ohio State University. The author has contributed to research in topics: Hsp90 inhibitor & Ganetespib. The author has an hindex of 17, co-authored 54 publications receiving 1290 citations.
Papers
More filters
Journal ArticleDOI
Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Weiwen Ying,Zhenjian Du,Lijun Sun,Kevin Foley,David A. Proia,Ronald K. Blackman,Dan Zhou,Takayo Inoue,Noriaki Tatsuta,Jim Sang,Shuxia Ye,Jamie Acquaviva,Luisa Shin Ogawa,Yumiko Wada,James Barsoum,Keizo Koya +15 more
TL;DR: It is shown that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors.
Patent
Triazole compounds that modulate HSP90 activity
Weiwen Ying,David James,Shijie Zhang,Teresa Przewloka,Junghyun Chae,Dinesh Chimmanamada,Chi-Wan Lee,Elena Kostik,Howard P. Ng,Kevin Foley,Zhenjian Du,James Barsoum +11 more
TL;DR: In this paper, the authors proposed methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof, by administering to the subject a substituted triazole compound or a composition comprising such a compound.
Journal ArticleDOI
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Takeshi Shimamura,Samanthi A. Perera,Kevin Foley,Jim Sang,Scott J. Rodig,Takayo Inoue,Liang Chen,Danan Li,Julian Carretero,Yu-Chen Li,Papiya Sinha,Christopher D. Carey,Christa L. Borgman,John-Paul Jimenez,Matthew Meyerson,Weiwen Ying,James Barsoum,Kwok-Kin Wong,Geoffrey I. Shapiro +18 more
TL;DR: Ganetespib has greater potency than 17-AAG and potential efficacy against several NSCLC subsets, including those harboring EGFR or ERBB2 mutation and also showed activity against mouse lung adenocarcinomas driven by oncogenic ER BB2 YVMA.
Journal ArticleDOI
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Tzu-yin Lin,Misty D. Bear,Zhenjian Du,Kevin Foley,Weiwen Ying,James Barsoum,Cheryl A. London +6 more
TL;DR: In this paper, a novel HSP90 inhibitor, STA-9090, was evaluated against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs) and fresh malignant mast cells.
Journal Article
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit dependent and independent malignant mast cell tumors.
TL;DR: A novel HSP90 inhibitor, STA-9090, exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clinical setting against mast cell malignancies.